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Thrombolysis-associated ventricular fibrillation: is it 
reperfusion, the drug or what?
See page 213 for the article to which this Editorial refers
Primary ventricular fibrillation occurs frequently in 
the setting of acute myocardial infarction and takes 
the lives of about 30% of patients in the first hour of 
symptoms. The mechanisms by which these fatal 
arrhythmias are initiated are, however, still not com­
pletely elucidated. A certain anatomical substrate, a 
prerequisite for primary ventricular fibrillation, can­
not be identified. Prevention of primary ventricular 
fibrillation in acute myocardial infarction would be 
a major step forward in the reduction of mortality, 
but so far only lidocain has shown some efficacyE1], 
although the side effects of this prophylaxis hampers 
its general use.
Reperfusion therapy is a major leap forward 
in the treatment of acute myocardial infarction and 
has been shown to reduce mortality by at least 25%[2l  
The mechanism of benefit is very clear: reperfusion 
leads to a smaller infarct size, to preservation of 
residual left ventricular function and, therefore, to 
improved survival. Reperfusion of ischaemic myo­
cardium might also result in so-called reperfusion 
damage, but in humans this has not been substanti­
ated. Another feared complication of rapid resto­
ration of blood flow in ischaemic myocardium is the 
occurrence of ventricular arrhythmia. Accelerated 
idioventricular rhythm is a well known complication 
of reperfusion, but this arrhythmia is generally well 
tolerated and not associated with any morbidity. 
Primary ventricular fibrillation, however, is seen less 
with intravenous thrombolytic therapy than with- 
oulP\ These observations have also been made in 
smaller controlled trials of thrombolysis for acute 
myocardial infarction. Finally, the occurrence of pri­
mary ventricular fibrillation is associated with higher 
in-hospital mortality, but not with worsened survival 
after hospital discharge^. The clinical findings 
suggest that primary ventricular fibrillation is associ­
ated with larger infarcts and possibly with a lack of 
successful reperfusion.
In the well known EMIP study, pre-hospital 
administration of anistreplase was compared to 
in-hospital anistreplase treatment1^ . It was clearly 
shown that the time gain of about 60 min resulted in 
a reduction in mortality of about 15%. The two 
treatment periods in the study design revealed very 
interesting findings on the occurrence of primary 
ventricular fibrillation in very early (pre-hospital) and
early (in-hospital) thrombolysis for acute myocardial 
infarction. The EM IP study group clearly shows that 
the incidence of primary ventricular fibrillation peaks 
after treatment with anistreplase, but not with 
placebo in each of the two treatment periods[6l  The 
blinded nature o f the treatment allocation makes the 
results convincing. So far, no study has been pre­
sented that performed close monitoring of early 
arrhythmia in patients undergoing thrombolytic 
therapy.
The authors speculate about the mechanism of 
this increased incidence of primary ventricular fibril­
lation. There is little doubt that the observations 
by Boissel et al. are correct and one wonders why 
the peaked incidence directly after therapy was not 
reported in the much larger controlled trials of 
thrombolysis in acute myocardial infarction, such as 
GISSI-1 and ISIS-2. Maybe in the latter two studies 
close monitoring of patients in the first hour after 
initiation of therapy was not performed sufficiently 
well for the incidence of primary ventricular fibril­
lation to be studied specifically and to be reported in 
the patient record forms. This might explain the 
discrepancy between the EMIP experience and that in 
GISSI-1 and ISIS-2.
A more scientific discrepancy is the relation­
ship between the occurrence of ventricular fibrillation 
in the early hours of myocardial infarction and 
the worsened in-hospital prognosis, as reported by 
others[4]. I f  primary ventricular fibrillation is caused 
by reperfusion, the prognosis of patients with primary 
ventricular fibrillation should be better than patients 
who do no t reperfuse. It is also possible that more 
than one mechanism induces excess primary ven­
tricular fibrillation following thrombolysis. Unfor­
tunately, no angiography was performed in these 
patients. Angiographic substrates in patients with 
and without primary ventricular fibrillation after 
thrombolytic therapy are not very well studied. Small 
reports do not show any specific coronary angio­
graphic characteristic in patients with primary ven­
tricular fibrillation compared to those without^. A 
definite answer on the mechanism of the observed 
excess incidence of ventricular fibrillation following 
anistreplase may never be confirmed. It is also poss­
ible that the drug itself initiates the arrhythmia, 
whether the patient develops reperfusion or not.
Editorials 173
However, it is less likely that the drug itself causes 
this, since this was not observed in the single large 
randomized clinical trial with anistreplase for acute 
myocardial infarction^. In direct comparative trials 
with other thrombolytics, a higher incidence o f ven­
tricular fibrillation with anistreplase is not reported 
either, bu t it is possible that the incidence is under- 
reported for the above reasons.
In conclusion, primary ventricular fibrillation 
peaks after initiation of early anistreplase therapy for 
acute myocardial infarction both pre-hospital and 
in-hospital. However, this complication can easily be 
minimized and is not by itself a mechanism of early 
mortality. However, as reported by other study 
groups, the occurrence of ventricular fibrillation in 
the early hours of acute myocardial infarction is an 
unfavourable prognostic sign for which there is no 
plausible explanation.
F. W. A. VERHEUGT
University Hospital Nijmegan, The Netherlands
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